At 1.20 pm Tripep was down 65% at 4.62 kronor, while the OMX Stockholm was down 0.53% at 342.90.
“Naturally we are very disappointed,” said Tripep. “A study report will be prepared but right now it is hard to see a continuation of the alphaHGA project”.
Tripep’s share price went vertical in January, reaching a high of 17.90 kronor amid optimism surrounding the trials in Thailand.
Tripep said it will now focus its research and resources on Hepatitis C.